Pharmacokinetics of ribavirin in patients with hepatitis C virus
Article first published online: 12 JUL 2006
British Journal of Clinical Pharmacology
Volume 62, Issue 6, pages 710–714, December 2006
How to Cite
Wade, J. R., Snoeck, E., Duff, F., Lamb, M. and Jorga, K. (2006), Pharmacokinetics of ribavirin in patients with hepatitis C virus. British Journal of Clinical Pharmacology, 62: 710–714. doi: 10.1111/j.1365-2125.2006.02704.x
- Issue published online: 12 JUL 2006
- Article first published online: 12 JUL 2006
- Received 12 September 2005 Accepted5 April 2006 Published OnlineOpen12 July 2006
- hepatitis C;
- peginterferon alfa-2a (40KD);
A population pharmacokinetic analysis was performed using plasma concentration data (n = 7025) from 380 patients to examine the relationship between ribavirin dose and its pharmacokinetics.
Ribavirin pharmacokinetics were described by a three-compartment model with sequential zero-order and a first-order absorption processes. Interoccasion variability and food effects were included.
Lean body weight (range 41–91 kg) was the only covariate with a clinically significant influence on ribavirin pharmacokinetics, affecting clearance (15.3–23.9 l h−1) and the volume of the larger peripheral compartment.
The model provided a good description of the available data, confirmed by accurate estimates of parameter values and low residual variability (17%).